Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study

Tanaka, Yoshiya; Mizukami, Akiko; Kobayashi, Akihiro; Ito, Chie; Matsuki, Taizo

doi:10.1111/1756-185x.13363

Cited by 43 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…of SLE treatment may not be optimal for patients with SLE to prevent flares or reduce detrimental effects. HRU in this study was similar to the results reported by Tanaka et al 14 in a retrospective, observational cohort study conducted using claims data of Japanese patients who were diagnosed with SLE between April 2010 and March 2012. These patients were followed-up for 3 years and data on HRU and costs were analyzed.…”

Section: Discussionsupporting

confidence: 90%

“…The meagre number of drug classes observed could be explained by the stringent treatment algorithm that defined the LoT in this study as well as by the presence of a standard treatment algorithm for the clinical management of SLE 12,13 . Our treatment pattern assessment was comparable to a previous Japanese study 14 as well with reports from other countries 37,38 . Utilization of antimalarials (e.g.…”

Section: Discussionsupporting

confidence: 88%

“…Similar guidelines for the management of SLE do not exist in Japan. However, Tanaka et al 14 after retrospectively analyzing claims data of Japanese patients who were diagnosed with SLE between April 2010 and March 2012 and had follow-up data for 3 years, reported corticosteroids to be the mainstay of SLE therapy in Japan, with other medicationsexcept hydroxychloroquinebeing utilized more or less in line with the guidelines of other countries.…”

Section: Introductionmentioning

confidence: 99%

“…The economic impact of SLE is two-fold, including both cost of treatment and productivity losses due to complications of SLE, as 25-60% of patients develop renal disease over time and may require expensive treatments and procedures such as dialysis and a transplant [15][16][17] . Tanaka et al 14 reported that all patients with SLE in Japan had at least one outpatient visit, while 39.3% had been hospitalized at least once. The mean total all-cause direct medical cost per patient over 3 years was ¥2,913,509 with costs rising proportionally to disease severity.…”

Section: Introductionmentioning

confidence: 99%

“…Limited evidence exists in the literature with respect to comorbid health and physical conditions, treatment patterns persistency, and rates of switching to or augmentation with alternative therapies 14,19,20 . The latest study 14 evaluating the above outcomes assessed claims data for a maximum of 3 years from the index diagnosis period (2010-2012). Moreover, the number of patients who met the inclusion criteria was small (n ¼ 295).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study

Miyazaki¹,

Sruamsiri

Mahlich

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

Aim: To describe the characteristics and medication treatment patterns, healthcare resource utilization (HRU), and associated costs in Japanese patients with systemic lupus erythematosus (SLE). Methods: Claims data from the Japan Medical Data Center (JMDC) database were used to identify patients with SLE-related claims from 2010 to 2017. Algorithms were developed to retrospectively categorize patients by disease severity, treatment experience, and SLE-related manifestations such as lupus nephritis and central nervous system lupus. Descriptive and multivariate analyses were used to describe treatment pattern and estimate HRU and associated costs for the SLE cohort overall and by disease severity and complications. Results: Among 4,733 eligible patients, 2,072 (43.8%) were treatment naïve, 2,214 (46.8%) were previously treated for SLE, and 447 (9.4%) did not receive any treatment. Mean (SD) age of the total SLE cohort was 45.2 (13.1) years and mean (SD) follow-up duration was 1,137.3 (758.0) d. Based on disease severity, 1,383 (29.2%) patients had mild, 2,619 (55.3%) patients had moderate, and 731 (15.4%) patients had severe SLE. Patients on glucocorticoids (both oral and parenteral) received add-on medications the most (35.5%, p < .001). Mean annual cost per SLE patient in the post-index period, inclusive of hospitalizations, outpatient visits, and pharmacy was ¥436,836; ¥1,010,772; and ¥2,136,780 for patients with mild, moderate, and severe SLE, respectively. Limitations: The database only captured information on patients up to 75 years of age. Due to the nature of the database, biases regarding conditions that attribute to the spectrum of SLE severity, flare incidences, or individual physical status cannot be ruled out. Conclusions: This study describes the treatment patterns and economic burden experienced by Japanese patients with SLE. The results highlight an unmet need to derive better treatment strategies for patients with SLE to effectively address the disease burden in Japan.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study

Miyazaki¹,

Sruamsiri

Mahlich

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region

Tanaka

O’Neill

et al. 2022

Arthritis Care & Research

Self Cite

View full text Add to dashboard Cite

Objective. To understand the epidemiology, current treatment, and disease burden of systemic lupus erythematosus (SLE) in the Asia Pacific (APAC) region.Methods. A targeted literature review of published evidence on SLE in the APAC region was conducted, using the Medline database (2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018), conference proceedings, and other supplementary sources.Results. The current review identified 70 studies conducted in China (n = 15), Japan (n = 13), Taiwan (n = 12), Korea (n = 9), Australia (n = 7), Hong Kong (n = 6), Singapore (n = 4), and multiple places within the APAC region (n = 4). Incidence rates (per 100,000 persons per year) ranged from 0.9-8.4, while prevalence rates ranged from 3.7-127 (per 100,000 persons); however, recent data were limited. Asian patients with SLE were reported to have higher disease severity, disease activity (higher SLE disease activity index scores), and organ damage accrual, along with increased morbidity, mortality, and susceptibility to renal involvement compared with other ethnicities in the APAC region. The risk of developing SLE is higher in the Asian population. Routinely used SLE therapies included belimumab, hydroxychloroquine, cyclophosphamide, tacrolimus, azathioprine, mycophenolate mofetil, and glucocorticoids; however, prescribing patterns varied across the region. Increased disease activity was associated with high economic burden and poor quality of life for SLE patients in the APAC region.Conclusion. SLE remains a disease with a significant unmet medical need for an innovative therapy that is well-tolerated and effective for patients in the APAC region. Further evidence is required to better characterize the disease and fully capture the burden and impact of SLE in the APAC region. This review has highlighted where there is a paucity of data from patients across the APAC region.

show abstract

Fatigue and Pain Measurements in Systemic Lupus Erythematosus

Ajrawat

Strand

Matsos

et al. 2021

Outcome Measures and Metrics in Systemic Lupus Erythematosus

View full text Add to dashboard Cite

Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study

Abstract: This descriptive study provides information on the economic burden and clinical characteristics of Japanese patients with SLE based on claims data; high levels of HRU and direct medical costs were exhibited, particularly in patients with moderate or severe disease.

Cited by 43 publications

References 34 publications

Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study

Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study

Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region

Fatigue and Pain Measurements in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About